A Multicenter, Open-label, Single-arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib in Korean Patients With Rheumatoid Arthritis
Latest Information Update: 21 Jul 2025
At a glance
- Drugs Filgotinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Eisai Korea
Most Recent Events
- 09 Jul 2025 Planned End Date changed from 27 Oct 2025 to 19 Mar 2026.
- 09 Jul 2025 Planned primary completion date changed from 30 Jun 2025 to 26 Feb 2026.
- 02 Dec 2024 Status changed from not yet recruiting to recruiting.